Keryx Biopharmaceuticals Inc. (KERX) Short Interest Update
Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) was the recipient of a large growth in short interest in September. As of September 15th, there was short interest totalling 19,312,877 shares, a growth of 14.6% from the August 31st total of 16,850,092 shares. Currently, 18.8% of the company’s stock are sold short. Based on an average daily trading volume, of 1,795,368 shares, the days-to-cover ratio is presently 10.8 days.
In other Keryx Biopharmaceuticals news, CFO Scott A. Holmes sold 4,935 shares of the business’s stock in a transaction on Friday, July 29th. The shares were sold at an average price of $7.36, for a total value of $36,321.60. The sale was disclosed in a document filed with the SEC, which is available at this link. 3.08% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of KERX. Janney Montgomery Scott LLC boosted its position in Keryx Biopharmaceuticals by 99.0% in the second quarter. Janney Montgomery Scott LLC now owns 84,209 shares of the biopharmaceutical company’s stock worth $490,000 after buying an additional 41,894 shares during the period. Shufro Rose & Co. LLC boosted its position in Keryx Biopharmaceuticals by 41.6% in the second quarter. Shufro Rose & Co. LLC now owns 78,000 shares of the biopharmaceutical company’s stock worth $516,000 after buying an additional 22,900 shares during the period. Royce & Associates LP boosted its position in Keryx Biopharmaceuticals by 32.2% in the first quarter. Royce & Associates LP now owns 451,725 shares of the biopharmaceutical company’s stock worth $2,110,000 after buying an additional 110,000 shares during the period. Norges Bank bought a new position in Keryx Biopharmaceuticals during the fourth quarter worth approximately $9,150,000. Finally, Geode Capital Management LLC boosted its position in Keryx Biopharmaceuticals by 5.4% in the first quarter. Geode Capital Management LLC now owns 699,895 shares of the biopharmaceutical company’s stock worth $3,268,000 after buying an additional 36,038 shares during the period. 61.13% of the stock is owned by hedge funds and other institutional investors.
Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) opened at 5.31 on Friday. The company’s market cap is $562.30 million. Keryx Biopharmaceuticals has a 12 month low of $2.80 and a 12 month high of $7.80. The company’s 50 day moving average is $4.63 and its 200-day moving average is $5.41.
Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its earnings results on Monday, August 1st. The biopharmaceutical company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by $0.14. The company earned $9.30 million during the quarter, compared to the consensus estimate of $8.60 million. Keryx Biopharmaceuticals had a negative return on equity of 172.04% and a negative net margin of 590.50%. The firm’s revenue was up 272.0% compared to the same quarter last year. During the same period last year, the company posted ($0.26) EPS. Analysts expect that Keryx Biopharmaceuticals will post ($1.24) EPS for the current fiscal year.
KERX has been the topic of a number of recent analyst reports. Brean Capital lowered shares of Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, August 2nd. FBR & Co reiterated a “buy” rating and issued a $13.00 price objective on shares of Keryx Biopharmaceuticals in a report on Monday, July 25th. Cowen and Company reiterated a “neutral” rating on shares of Keryx Biopharmaceuticals in a report on Wednesday, August 3rd. Maxim Group lowered shares of Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, August 1st. Finally, Zacks Investment Research lowered shares of Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 3rd. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $7.75.
About Keryx Biopharmaceuticals
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company’s product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis.
Receive News & Stock Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related stocks with our FREE daily email newsletter.